

Karl Andersson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1984352/publications.pdf>

Version: 2024-02-01

55
papers

1,848
citations

318942

23
h-index

312153

41
g-index

55
all docs

55
docs citations

55
times ranked

2386
citing authors

#	ARTICLE	IF	CITATIONS
1	The Clinical Course of Alcohol Use Disorder Depicted by Digital Biomarkers. <i>Frontiers in Digital Health</i> , 2021, 3, 732049.	1.5	4
2	A real-time cell-binding assay reveals dynamic features of STxB-Gb3 cointernalization and STxB-mediated cargo delivery into cancer cells. <i>FEBS Letters</i> , 2020, 594, 2406-2420.	1.3	2
3	Breathalyser-Based eHealth Data Suggest That Self-Reporting of Abstinence Is a Poor Outcome Measure for Alcohol Use Disorder Clinical Trials. <i>Alcohol and Alcoholism</i> , 2020, 55, 237-245.	0.9	11
4	Maximum Time Between Tests: A Digital Biomarker to Detect Therapy Compliance and Assess Schedule Quality in Measurement-Based eHealth Systems for Alcohol Use Disorder. <i>Alcohol and Alcoholism</i> , 2019, 54, 70-72.	0.9	6
5	Real-time Monitoring using a breathalyzer-based eHealth system can identify lapse/relapse patterns in alcohol use disorder Patients. <i>Alcohol and Alcoholism</i> , 2018, 53, 368-375.	0.9	17
6	Detecting ligand interactions in real time on living bacterial cells. <i>Applied Microbiology and Biotechnology</i> , 2018, 102, 4193-4201.	1.7	3
7	Thermodynamic and kinetic approaches for evaluation of monoclonal antibody - Lipoprotein interactions. <i>Analytical Biochemistry</i> , 2017, 518, 25-34.	1.1	16
8	Novel Real-Time Proximity Assay for Characterizing Multiple Receptor Interactions on Living Cells. <i>Analytical Chemistry</i> , 2017, 89, 13212-13218.	3.2	8
9	Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells. <i>Frontiers in Immunology</i> , 2017, 8, 455.	2.2	51
10	Impact of assay temperature on antibody binding characteristics in living cells: A case study. <i>Biomedical Reports</i> , 2017, 7, 400-406.	0.9	21
11	Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of ICFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material. <i>PLoS ONE</i> , 2016, 11, e0145545.	1.1	8
12	Characterizing and Controlling the Loading and Release of Cationic Amphiphilic Peptides onto and from PEG-Stabilized Lipodisks. <i>Langmuir</i> , 2016, 32, 12091-12099.	1.6	16
13	Avidity characterization of genetically engineered T-cells with novel and established approaches. <i>BMC Immunology</i> , 2016, 17, 23.	0.9	15
14	Deciphering the Stepwise Binding Mode of HRG1 ² to HER3 by Surface Plasmon Resonance and Interaction Map. <i>PLoS ONE</i> , 2015, 10, e0116870.	1.1	8
15	Automated functional characterization of radiolabeled antibodies. <i>Nuclear Medicine Communications</i> , 2014, 35, 767-776.	0.5	8
16	Methods for Radiolabelling of Monoclonal Antibodies. <i>Methods in Molecular Biology</i> , 2014, 1060, 309-330.	0.4	40
17	Conjugation Effects on Antibody-Drug Conjugates: Evaluation of Interaction Kinetics in Real Time on Living Cells. <i>Molecular Pharmaceutics</i> , 2014, 11, 4154-4163.	2.3	14
18	Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay. <i>Journal of Pharmacological and Toxicological Methods</i> , 2014, 70, 145-151.	0.3	2

#	ARTICLE	IF	CITATIONS
19	Operator Dependent Choice of Prostate Cancer Biopsy Has Limited Impact on a Gene Signature Analysis for the Highly Expressed Genes IGFBP3 and F3 in Prostate Cancer Epithelial Cells. PLoS ONE, 2014, 9, e109610.	1.1	10
20	Exploring Time-Resolved Characterization of the Heterogeneity and Dynamics of Ligand-Receptor Interactions on Living Cells. Journal of Analytical Oncology, 2014, 3, .	0.1	9
21	Detecting ligand interactions with G protein-coupled receptors in real-time on living cells. Biochemical and Biophysical Research Communications, 2013, 441, 820-824.	1.0	11
22	Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging. Nuclear Medicine and Biology, 2013, 40, 378-386.	0.3	15
23	Evaluating real-time immunohistochemistry on multiple tissue samples, multiple targets and multiple antibody labeling methods. BMC Research Notes, 2013, 6, 542.	0.6	12
24	[^{99m} Tc(CO) ₃]+-(HE) ₃ -ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 439-449.	3.3	38
25	<i>In Vivo</i> and <i>In Vitro</i> Studies on Renal Uptake of Radiolabeled Affibody Molecules for Imaging of HER2 Expression in Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 187-195.	0.7	30
26	Development of a rapid low cost fluorescent biosensor for the detection of food contaminants. Biosensors and Bioelectronics, 2013, 41, 96-102.	5.3	24
27	Evaluation of Real-Time Immunohistochemistry and Interaction Map as an Alternative Objective Assessment of HER2 Expression in Human Breast Cancer Tissue. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 497-505.	0.6	3
28	Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach. Molecular and Clinical Oncology, 2013, 1, 343-352.	0.4	32
29	Deciphering complex protein interaction kinetics using Interaction Map. Biochemical and Biophysical Research Communications, 2012, 428, 74-79.	1.0	37
30	Generation and Evaluation of Bispecific Affibody Molecules for Simultaneous Targeting of EGFR and HER2. Bioconjugate Chemistry, 2012, 23, 1802-1811.	1.8	26
31	Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with ¹²⁵ I-EGF. PLoS ONE, 2011, 6, e24739.	1.1	77
32	Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation. Nuclear Medicine Communications, 2011, 32, 863-867.	0.5	15
33	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. International Journal of Oncology, 2011, 40, 1677-82.	1.4	20
34	Avoiding false negative results in specificity analysis of protein-protein interactions. Journal of Molecular Recognition, 2011, 24, 81-89.	1.1	12
35	Comparing the Epidermal Growth Factor Interaction with Four Different Cell Lines: Intriguing Effects Imply Strong Dependency of Cellular Context. PLoS ONE, 2011, 6, e16536.	1.1	46
36	Real-time immunohistochemistry analysis of embedded tissue. Applied Radiation and Isotopes, 2010, 68, 2372-2376.	0.7	6

#	ARTICLE	IF	CITATIONS
37	Antibody-antigen interactions: What is the required time to equilibrium?. Nature Precedings, 2010, , .	0.1	8
38	The influence of Bz-DOTA and CHX-Aâ€³-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1460-1468.	3.3	27
39	Characterization of ¹¹¹ In and ¹⁷⁷ Lu-labeled antibodies binding to CD44v6 using a novel automated radioimmunoassay. Journal of Molecular Recognition, 2008, 21, 179-183.	1.1	22
40	Real-time viability assay based on ⁵¹ Cr retention in adherent cells. BioTechniques, 2008, 44, 237-240.	0.8	7
41	Radionuclide Therapy of HER2-Positive Microxenografts Using a ¹⁷⁷ Lu-Labeled HER2-Specific Affibody Molecule. Cancer Research, 2007, 67, 2773-2782.	0.4	203
42	Label-free kinetic binding data as a decisive element in drug discovery. Expert Opinion on Drug Discovery, 2006, 1, 439-446.	2.5	26
43	Automated, high-resolution cellular retention and uptake studies in vitro. Applied Radiation and Isotopes, 2006, 64, 901-905.	0.7	70
44	Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area. Applied Radiation and Isotopes, 2006, 64, 32-37.	0.7	46
45	Replacing affinity with binding kinetics in QSAR studies resolves otherwise confounded effects. Journal of Chemometrics, 2006, 20, 370-375.	0.7	13
46	Kinetic determinations of molecular interactions using Biacoreâ€™ minimum data requirements for efficient experimental design. Journal of Molecular Recognition, 2005, 18, 307-317.	1.1	75
47	[¹⁷⁷ Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1457-1462.	3.3	61
48	Structural Modeling Extends QSAR Analysis of Antibody-Lysozyme Interactions to 3D-QSAR. Biophysical Journal, 2003, 84, 2264-2272.	0.2	25
49	QSAR studies applied to the prediction of antigen-antibody interaction kinetics as measured by BIACORE. Protein Engineering, Design and Selection, 2002, 15, 373-382.	1.0	29
50	Kinetic and Affinity Predictions of a Protein-Protein Interaction Using Multivariate Experimental Design. Journal of Biological Chemistry, 2002, 277, 29897-29907.	1.6	46
51	Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space. Journal of Molecular Recognition, 2001, 14, 62-71.	1.1	34
52	Biosensor Analysis of Drug-Target Interactions: Direct and Competitive Binding Assays for Investigation of Interactions between Thrombin and Thrombin Inhibitors. Analytical Biochemistry, 2000, 278, 1-13.	1.1	133
53	Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels. Journal of Medicinal Chemistry, 2000, 43, 1986-1992.	2.9	288
54	Kinetic characterization of the interaction of the Z-fragment of protein A with mouse-IgG3 in a volume in chemical space. , 1999, 37, 494-498.		12

#	ARTICLE	IF	CITATIONS
55	Exploring buffer space for molecular interactions. , 1999, 12, 310-315.		50